Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven I Sherman

Showing results (71-80 of 160) with videos related to

Pageof 16
Sort By:
The Journal of Clinical Endocrinology and Metabolism|December 31, 2020
Distant Metastases From Childhood Differentiated Thyroid Carcinoma: Clinical Course and Mutational LandscapeMarloes Nies, Rena Vassilopoulou-Sellin, Roland L Bassett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2017
Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial ImprovementChad Tang, Steven I Sherman, Mellanie Price, et al.
The Journal of Clinical Endocrinology and Metabolism|October 13, 2009
Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experienceApostolia Maria Tsimberidou, Christos Vaklavas, Sijin Wen, et al.
BMC Cancer|August 13, 2011
Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancerMarcia S Brose, Christopher M Nutting, Steven I Sherman, et al.
Journal of the American College of Surgeons|March 31, 2004
Surgical management of hereditary pheochromocytomaLinwah Yip, Jeffrey E Lee, Suzanne E Shapiro, et al.
Thyroid : Official Journal of the American Thyroid Association|March 16, 2013
Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutationKevin B Kim, Maria E Cabanillas, Alexander J Lazar, et al.
Surgery|December 20, 2002
Improving the yield of preoperative parathyroid localization: technetium Tc 99m-sestamibi imaging after thyroid suppressionRichard E Royal, Ebrahim S Delpassand, Suzanne E Shapiro, et al.
American Journal of Surgery|December 16, 2003
Potential role for intraoperative gamma probe identification of normal parathyroid glandsLee C Pederson, Suzanne E Shapiro, Herbert A Fritsche, et al.
Head & Neck|April 11, 2009
Hypothyroidism in older patients with head and neck cancer after treatment with radiation: a population-based studyGrace L Smith, Benjamin D Smith, Adam S Garden, et al.
Thyroid : Official Journal of the American Thyroid Association|July 21, 2005
RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumorsMaria A Kouvaraki, Suzanne E Shapiro, Nancy D Perrier, et al.
Pageof 16

Showing results (71-80 of 160) with videos related to

Sort By:
Pageof 16
The Journal of Clinical Endocrinology and Metabolism|December 31, 2020
Distant Metastases From Childhood Differentiated Thyroid Carcinoma: Clinical Course and Mutational LandscapeMarloes Nies, Rena Vassilopoulou-Sellin, Roland L Bassett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2017
Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial ImprovementChad Tang, Steven I Sherman, Mellanie Price, et al.
The Journal of Clinical Endocrinology and Metabolism|October 13, 2009
Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experienceApostolia Maria Tsimberidou, Christos Vaklavas, Sijin Wen, et al.
BMC Cancer|August 13, 2011
Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancerMarcia S Brose, Christopher M Nutting, Steven I Sherman, et al.
Journal of the American College of Surgeons|March 31, 2004
Surgical management of hereditary pheochromocytomaLinwah Yip, Jeffrey E Lee, Suzanne E Shapiro, et al.
Thyroid : Official Journal of the American Thyroid Association|March 16, 2013
Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutationKevin B Kim, Maria E Cabanillas, Alexander J Lazar, et al.
Surgery|December 20, 2002
Improving the yield of preoperative parathyroid localization: technetium Tc 99m-sestamibi imaging after thyroid suppressionRichard E Royal, Ebrahim S Delpassand, Suzanne E Shapiro, et al.
American Journal of Surgery|December 16, 2003
Potential role for intraoperative gamma probe identification of normal parathyroid glandsLee C Pederson, Suzanne E Shapiro, Herbert A Fritsche, et al.
Head & Neck|April 11, 2009
Hypothyroidism in older patients with head and neck cancer after treatment with radiation: a population-based studyGrace L Smith, Benjamin D Smith, Adam S Garden, et al.
Thyroid : Official Journal of the American Thyroid Association|July 21, 2005
RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumorsMaria A Kouvaraki, Suzanne E Shapiro, Nancy D Perrier, et al.
Pageof 16